Medivir AB (OSTO:MVIR)
kr 2.87 -0.08 (-2.71%) Market Cap: 321.92 Mil Enterprise Value: 165.94 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 60/100

Q2 2020 Medivir AB Earnings Call Transcript

Aug 20, 2020 / 12:00PM GMT
Release Date Price: kr9.55 (+1.57%)
Operator

Ladies and gentlemen, welcome to the Medivir AB Q2 report 2020. (Operator Instructions)

Today, I am pleased to present Uli Hacksell, CEO. Please begin your meeting.

Uli Hacksell;publ;Director
Medivir AB

()-

Thank you, and good afternoon. With me today are Magnus Christensen, who is the Chief Financial Officer; and Linda Basse, our Chief Medical Officer. With that, I will start out by asking Magnus to provide a financial summary of the second quarter.

Magnus Christensen;publ;CFO
Medivir AB

()-

Thank you, Uli. Please see Slide 3, where you can see the financial summary. You can see the summary for quarter 2 and the half year-end of June. And you can see the turnover for quarter 2 amounts to SEK 4 million, which is very similar to last year and relates to royalty income from Xerclear. Accumulated for the first 6 months of 2020 is SEK 11.4 million, this is almost double last year and it relates to both higher royalty income from Xerclear as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot